- Gene editing product finder
- Gene editing tools and information
- CRISPR/Cas9 knockouts
- CRISPR/Cas9 knockins
- Genome-wide screening
- Creating and screening for SNPs
- CRISPR/Cas9 delivery methods
- Cre recombinase
Gene editing of immune cells
A powerful tool for basic and clinical researchers is the ability to genetically modify immune cells using targeted genome engineering approaches such as CRISPR/Cas9 technology. However, inefficient delivery methods and low expression of CRISPR-Cas9 components in T cells have made the application of this technology to primary human immune cells a challenge. Using viral vectors or plasmids to apply CRISPR-Cas9 for genome editing in T cells results in low targeting efficiency and high toxicity. These issues, however, can be overcome by using electroporation to deliver Cas9 ribonucleoprotein complexes (RNPs) in tandem with single-stranded DNA templates for homology-directed repair (HDR). To help our customers circumvent some of these challenges, we share protocols developed by our R&D team for efficient editing of CD3+ Pan T cells and CD34+ cells using electroporation to deliver Cas9 RNPs and ssDNA templates.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.